Literature DB >> 25468161

Starting the battle to control non-alcoholic steatohepatitis.

Vlad Ratziu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25468161     DOI： 10.1016/S0140-6736(14)62010-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 2.  Pathobiology of liver fibrosis: a translational success story.

Authors:  Youngmin A Lee; Michael C Wallace; Scott L Friedman
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

3.  Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease.

Authors:  Lihua Jin; Rui Wang; Yanlin Zhu; Weili Zheng; Yaping Han; Fusheng Guo; Frank Bin Ye; Yong Li
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

Review 4.  Long Noncoding RNAs in Metabolic Syndrome Related Disorders.

Authors:  Magdalena Losko; Jerzy Kotlinowski; Jolanta Jura
Journal:  Mediators Inflamm       Date:  2016-11-02       Impact factor: 4.711

5.  Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD.

Authors:  Yanlin Zhu; Shuangshuang Xu; Yi Lu; Yijuan Wei; Benqiang Yao; Fusheng Guo; Xing Zheng; Yumeng Wang; Ying He; Lihua Jin; Yong Li
Journal:  Front Pharmacol       Date:  2020-05-14       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.